This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2010 Nov;53(5):795-6.

doi: 10.1016/j.jhep.2010.07.003. Epub 2010 Jul 24.

Fibroblast growth factor 21 as a biomarker for NAFLD: integrating pathobiology into clinical practice

Gareth Morris-Stiff, Ariel E Feldstein

PMID: 20800308
DOI: 10.1016/j.jhep.2010.07.003

Free article

Editorial

Fibroblast growth factor 21 as a biomarker for NAFLD: integrating pathobiology into clinical practice

Gareth Morris-Stiff et al. J Hepatol. 2010 Nov.

Free article

. 2010 Nov;53(5):795-6.

doi: 10.1016/j.jhep.2010.07.003. Epub 2010 Jul 24.

Authors

Gareth Morris-Stiff, Ariel E Feldstein

PMID: 20800308
DOI: 10.1016/j.jhep.2010.07.003

No abstract available

PubMed Disclaimer

Comment on

Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride.
Li H, Fang Q, Gao F, Fan J, Zhou J, Wang X, Zhang H, Pan X, Bao Y, Xiang K, Xu A, Jia W. Li H, et al. J Hepatol. 2010 Nov;53(5):934-40. doi: 10.1016/j.jhep.2010.05.018. Epub 2010 Jul 17. J Hepatol. 2010. PMID: 20675007

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science